Literature DB >> 15842359

Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome.

E Nestoridi1, O Tsukurov, R I Kushak, J R Ingelfinger, E F Grabowski.   

Abstract

BACKGROUND: The pathogenesis of Shiga toxin (Stx)-mediated childhood hemolytic uremic syndrome (HUS) is not fully delineated, although current evidence implicates a prothrombotic state. We hypothesized that the tissue factor (TF) pathway plays a major role in the pathophysiology of HUS.
MATERIALS AND METHODS: We measured cell surface TF activity in response to tumor necrosis factor-alpha (TNF-alpha) (20 ng mL(-1), 2-144 h), Stx-1 (10(-11) mol L(-1), 4-144 h), or their combination (TNF-alpha 22 h and Stx-1 for the last 0.5-4 h of TNF-alpha incubation) on human glomerular (microvascular) endothelial cells (HGECs) and human umbilical vein (macrovascular) endothelial cells (HUVECs). RESULTS AND
CONCLUSIONS: We observed that while TNF-alpha caused an increase in cell surface TF activity on both cell types, the combination of TNF-alpha and Stx-1 differentially affected HGECs. On these cells, TF activity was increased further by 2.67 +/- 0.38-fold (n = 38, P < 0.001), consistent with our parallel observation that Stx-1 binds to HGECs but not to HUVECs. Anti-TF antibody abolished functional TF while anti-tissue factor pathway inhibitor antibody enhanced TF activity. Stx-1 alone did not induce TF activity on either cell type. Measurement of TF antigen levels and quantitative real-time polymerase chain reaction demonstrated that exposure to TNF-alpha markedly increased TF protein and TF mRNA for HGECs, but the exposure to the combination of TNF-alpha and Stx-1 did not increase further the amount of either TF protein or TF mRNA. We conclude that cytokine-activated HGECs, but not HUVECs, undergo a significant augmentation of cell surface TF activity following exposure to Stx, suggesting an important role for TF in the coagulopathy observed in HUS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15842359     DOI: 10.1111/j.1538-7836.2005.01205.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  19 in total

1.  Tissue factor–dependent procoagulant activity of subtilase cytotoxin, a potent AB5 toxin produced by shiga toxigenic Escherichia coli.

Authors:  Hui Wang; James C Paton; Cheleste M Thorpe; Claudine S Bonder; Wai Yan Sun; Adrienne W Paton
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

Review 2.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.

Authors:  Deborah J Stearns-Kurosawa; Valta Collins; Scott Freeman; Diann Debord; Kiyotaka Nishikawa; Sun-Young Oh; Caitlin S Leibowitz; Shinichiro Kurosawa
Journal:  Pediatr Nephrol       Date:  2011-05-21       Impact factor: 3.714

4.  Shiga toxin subtypes display dramatic differences in potency.

Authors:  Cynthia A Fuller; Christine A Pellino; Michael J Flagler; Jane E Strasser; Alison A Weiss
Journal:  Infect Immun       Date:  2011-01-03       Impact factor: 3.441

Review 5.  Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.

Authors:  Andreas Bauwens; Josefine Betz; Iris Meisen; Björn Kemper; Helge Karch; Johannes Müthing
Journal:  Cell Mol Life Sci       Date:  2012-07-06       Impact factor: 9.261

Review 6.  Pathogenesis and prognosis of thrombotic microangiopathy.

Authors:  Masaomi Nangaku; Hiroshi Nishi; Toshiro Fujita
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

7.  Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression.

Authors:  Eirini Nestoridi; Rafail I Kushak; Olga Tsukurov; Eric F Grabowski; Julie R Ingelfinger
Journal:  Pediatr Nephrol       Date:  2007-11-30       Impact factor: 3.714

Review 8.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

Review 9.  Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.

Authors:  Trung C Nguyen; Miguel A Cruz; Joseph A Carcillo
Journal:  Crit Care Clin       Date:  2015-08-07       Impact factor: 3.598

Review 10.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.